News and Trends 31 Aug 2022 Laverock Therapeutics created to develop next generation of programmable cell therapies Laverock Therapeutics Ltd has been founded to develop a gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a seed funding round, the U.K. company has opened dedicated labs in the Stevenage Bioscience Catalyst, employing six new team members on top of its senior management team. Laverock Therapeutics started out […] August 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Research shows TikoMed’s ILB has the potential to treat neurodegenerative diseases including ALS Peer-review research published in Frontiers in Pharmacology supports the broad spectrum mechanism of action of Swedish biopharma company TikoMed’s ILB neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis […] August 31, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Potential new cancer treatment target discovered by researchers in Sweden A previously unknown mechanism that can control tumor growth in cultured cells and mice has been identified by researchers at the University of Gothenburg, Sweden. This discovery may potentially enable future development of new drugs against a range of cancer diseases. In a research article published in the journal Nature Communications, the Gothenburg scientists described […] August 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Bactolife receives $5M in new funding to address gut infections worldwide Bactolife has received an investment of $5 million from The Bill & Melinda Gates Foundation to accelerate the use of its technology platform that develops binding proteins for gut infections. The news was announced today (August 30) that in line with the foundation’s charitable mission, the investment would help develop the binding proteins which the […] August 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 30 Aug 2022 Biotech incubators scramble to tackle lab space crunch Biotech startups are finding it hard to source lab space in London. Incubators such as Scale Space in the White City hub aim to ease up the pressure by opening flexible lab leases in the city. The COVID-19 pandemic has hammered home the importance of biotechnology in society. As a result, the last few years […] August 30, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Scientists unravel mystery behind neurodegenerative disease protein Scientists have unraveled the mystery behind the mechanism behind a type of protein that leads to a progressive nervous system disease. In a study, recently published in the journal Physical Chemistry Chemical Physics, the researchers say that the RNA-binding ‘fused in sarcoma’ (FUS) protein transitions between liquid and solid phases inside cells. The scientists from […] August 30, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Artificial intelligence-based algorithm to be used for reporting of lymph node status in colon cancer A collaboration looking at the development of an artificial intelligence (AI)-based digital pathology solution to detect cancer within lymph nodes from colorectal surgery cases has been announced today (August 30). Indica Labs, which works in quantitative digital pathology and image management solutions, has joined forces with The Industrial Centre for Artificial Intelligence Research in Digital […] August 30, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Hemophilia drug from Sanofi and Sobi has license application accepted for priority review by FDA The Biologics License Application (BLA) for Efanesoctocog alfa, a drug to treat the rare and life-threatening blood disease, hemophilia A, has been accepted for priority review by the U.S. Food and Drug Administration (FDA). Efanesoctocog alfa (BIVV001) is being developed and commercialized as part of a collaboration between Sanofi and Sobi was given the target […] August 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Sponsored by Computomics 30 Aug 2022 Metagenomics: unlocking the secrets of microbial communities The combination of advanced sequencing technologies and user-friendly data analysis solutions is bringing metagenomics into the reach of more scientists, creating new opportunities to ask and answer exciting research questions. New ways to look at microbes Metagenomics is a relatively new field that is radically changing how microbial analyses are performed and making it possible […] August 30, 2022 - 6 minutesmins - By Julia Kaiser Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Vilya emerges to target disease biology VILYA, Inc. (Vilya), a biotech company aiming to create a new class of medicines to precisely target disease biology, launched today. Vilya is co-founded by scientists from the Institute of Protein Design (IPD) led by David Baker, and ARCH Venture Partners. The company’s platform, powered by advanced machine learning, taps into uncharted chemical space to […] August 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Grid Biosciences signs agreement with NIH for Epstein-Barr virus vaccine Grid Biosciences has signed a license agreement for the development of a vaccine against Epstein-Barr virus (EBV) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The agreement includes access to NIH’s patent rights in EBV envelope proteins that the virus uses to gain entry into […] August 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 AIVITA Biomedical announces publication of trial results of its COVID-19 vaccine Safety and efficacy results from phase 1 and 2 clinical trials looking at a Covid-19 vaccine made at point-of-care by third party personnel have been published. AIVITA Biomedical Inc., a biotech specializing in cell applications, made the announcement today (August 29). The results were published in the article in the journal Human Vaccines & Immunotherapeutics. […] August 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email